HSBC Maintains Reduce on Biogen, Raises Price Target to $175

Benzinga Newsdesk www.benzinga.com Positive 65.8%

Neg 0% Neu 0% Pos 65.8%

HSBC analyst Rajesh Kumar maintains Biogen (NASDAQ:BIIB) with a Reduce and raises the price target from $165 to $175.

Comments

No comments yet. Be the first!